Lineage, Inc. Common Stock (LINE)vsSL Green Realty Corp (SLG)
LINE
Lineage, Inc. Common Stock
$37.75
+0.96%
REAL ESTATE · Cap: $9.50B
SLG
SL Green Realty Corp
$53.08
+2.81%
REAL ESTATE · Cap: $4.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Lineage, Inc. Common Stock generates 438% more annual revenue ($5.37B vs $998.00M). LINE leads profitability with a -3.1% profit margin vs -16.7%. SLG earns a higher WallStSmart Score of 50/100 (D+).
LINE
Avoid35
out of 100
Grade: F
SLG
Hold50
out of 100
Grade: D+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Reasonable price relative to book value
Revenue surging 27.3% year-over-year
Areas to Watch
0.8% revenue growth
0.0% earnings growth
Operating margin of 3.7%
Elevated debt levels
Elevated debt levels
Weak financial health signals
ROE of -3.5% — below average capital efficiency
Earnings declined 98.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : LINE
The strongest argument for LINE centers on Price/Book.
Bull Case : SLG
The strongest argument for SLG centers on Price/Book, Revenue Growth. Revenue growth of 27.3% demonstrates continued momentum. PEG of 1.30 suggests the stock is reasonably priced for its growth.
Bear Case : LINE
The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.
Bear Case : SLG
The primary concerns for SLG are Debt/Equity, Piotroski F-Score, Return on Equity. Debt-to-equity of 1.51 is elevated, increasing financial risk.
Key Dynamics to Monitor
LINE profiles as a turnaround stock while SLG is a growth play — different risk/reward profiles.
SLG carries more volatility with a beta of 1.60 — expect wider price swings.
SLG is growing revenue faster at 27.3% — sustainability is the question.
LINE generates stronger free cash flow (186M), providing more financial flexibility.
Bottom Line
SLG scores higher overall (50/100 vs 35/100) and 27.3% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage, Inc. Common Stock
REAL ESTATE · REIT - INDUSTRIAL · USA
Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm dedicated to regenerative medicine, focusing on next-generation cell therapies targeting ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust strategic collaborations, Lineage is at the forefront of developing transformative treatment options that aim to improve patient outcomes significantly. The company's commitment to enhancing its diverse product pipeline and expediting clinical trials makes it an attractive investment opportunity for institutional investors seeking exposure in the rapidly evolving healthcare landscape.
Visit Website →Compare with Other REIT - INDUSTRIAL Stocks
Want to dig deeper into these stocks?